Healthcare & Life Sciences

Firefly Bio, Inc.

United Stateswww.jnj.com/media-center/press-releases/johnson-johnson-to-acquire-firefly-bio-inc-to-expand-oncology-pipeline-with-novel-degrader-antibody-conjugate-platform

acquiredacquired

acquired

Stage

Investors

About

Firefly Bio, Inc. develops the Firelink™ degrader antibody conjugate platform, a targeted technology designed to selectively degrade proteins in KRAS-driven and other solid tumor cancer cells.

Explore Firefly Bio, Inc.'s full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.